Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

H Miles Prince

Showing results (31-40 of 318) with videos related to

Pageof 32
Sort By:
Clinical Lymphoma, Myeloma & Leukemia|June 18, 2013
Duration of response in cutaneous T-cell lymphoma patients treated with denileukin diftitox: results from 3 phase III studiesMadeleine Duvic, Larisa Geskin, H Miles Prince
Plastic and Reconstructive Surgery|March 1, 2019
Molecular Drivers of Breast Implant-Associated Anaplastic Large Cell LymphomaPiers Blombery, Ella R Thompson, H Miles Prince
Investigational New Drugs|December 17, 2010
Histone deacetylase inhibitors: potential targets responsible for their anti-cancer effectMichael Dickinson, Ricky W Johnstone, H Miles Prince
Blood|August 22, 2009
How I treat mycosis fungoides and Sézary syndromeH Miles Prince, Sean Whittaker, Richard T Hoppe
Current Hematologic Malignancy Reports|October 23, 2018
Breast Implant-Associated Anaplastic Large Cell LymphomaP Rastogi, A K Deva, H Miles Prince
Immunotherapy|July 20, 2010
Chimeric T cells for adoptive immunotherapy of cancer: using what have we learned to plan for the futureStefan Peinert, Michael H Kershaw, H Miles Prince
Pathology|November 26, 2018
FDG-PET/CT findings, the vital clue to rare diagnosis of herpes simplex virus lymphadenitis simulating Richter transformationAbby P Douglas, Mohammad Atarod, H Miles Prince
Oncotarget|March 20, 2018
Brentuximab vedotin: targeting CD30 as standard in CTCLH Miles Prince, Ashish Gautam, Youn H Kim
Pharmacotherapy|July 26, 2006
Tumor lysis syndrome early after treatment with bortezomib for multiple myelomaMelita K Kenealy, H Miles Prince, Dirk Hönemann
Frontiers in Immunology|March 22, 2021
Understanding the Role of T-Cells in the Antimyeloma Effect of Immunomodulatory DrugsCriselle D'Souza, H Miles Prince, Paul J Neeson
Pageof 32

Showing results (31-40 of 318) with videos related to

Sort By:
Pageof 32
Clinical Lymphoma, Myeloma & Leukemia|June 18, 2013
Duration of response in cutaneous T-cell lymphoma patients treated with denileukin diftitox: results from 3 phase III studiesMadeleine Duvic, Larisa Geskin, H Miles Prince
Plastic and Reconstructive Surgery|March 1, 2019
Molecular Drivers of Breast Implant-Associated Anaplastic Large Cell LymphomaPiers Blombery, Ella R Thompson, H Miles Prince
Investigational New Drugs|December 17, 2010
Histone deacetylase inhibitors: potential targets responsible for their anti-cancer effectMichael Dickinson, Ricky W Johnstone, H Miles Prince
Blood|August 22, 2009
How I treat mycosis fungoides and Sézary syndromeH Miles Prince, Sean Whittaker, Richard T Hoppe
Current Hematologic Malignancy Reports|October 23, 2018
Breast Implant-Associated Anaplastic Large Cell LymphomaP Rastogi, A K Deva, H Miles Prince
Immunotherapy|July 20, 2010
Chimeric T cells for adoptive immunotherapy of cancer: using what have we learned to plan for the futureStefan Peinert, Michael H Kershaw, H Miles Prince
Pathology|November 26, 2018
FDG-PET/CT findings, the vital clue to rare diagnosis of herpes simplex virus lymphadenitis simulating Richter transformationAbby P Douglas, Mohammad Atarod, H Miles Prince
Oncotarget|March 20, 2018
Brentuximab vedotin: targeting CD30 as standard in CTCLH Miles Prince, Ashish Gautam, Youn H Kim
Pharmacotherapy|July 26, 2006
Tumor lysis syndrome early after treatment with bortezomib for multiple myelomaMelita K Kenealy, H Miles Prince, Dirk Hönemann
Frontiers in Immunology|March 22, 2021
Understanding the Role of T-Cells in the Antimyeloma Effect of Immunomodulatory DrugsCriselle D'Souza, H Miles Prince, Paul J Neeson
Pageof 32